Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Expert Opinion on Biological Therapy is Scopus-indexed (Q2, CiteScore 6.5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1471-2598Verify ISSN ↗1744-7682Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 89 / 328 | 73rd | Q2 |
| Clinical Biochemistry | 35 / 124 | 72nd | Q2 |
| Drug Discovery | 52 / 161 | 68th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q2, CiteScore 6.5.
Expert Opinion on Biological Therapy is Q2 in Pharmacology (rank 89 of 328), Q2 in Clinical Biochemistry (rank 35 of 124) and Q2 in Drug Discovery (rank 52 of 161), by CiteScore 2025.
Expert Opinion on Biological Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.5, which places it in quartile Q2 at the 73rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.045, quartile Q1, with an H-index of 112.
Expert Opinion on Biological Therapy is published by Taylor and Francis Ltd. Its print ISSN is 1471-2598 and its online ISSN is 1744-7682.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Expert Opinion on Biological Therapy has an h-index of 121 and a 2-year mean of 3.35 citations per paper (OpenAlex). Its Scopus CiteScore is 6.5, quartile Q2. On 2-year citations it ranks #101 of 319 Scopus journals in Pharmacology.
Expert Opinion on Biological Therapy published 115 papers in 2025; its busiest recent year was 2020 with 189. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2025–2026), authors are most often from United States (16.4%), Italy (14.2%) and China (13.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 6 retracted papers are recorded (1.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.